Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 2Stomach Neoplasms 1Peritoneal Neoplasms 1Neoplasms by Site 1Liver Neoplasms 1Liver Diseases 1Digestive System Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 685130-nm albumin-bound paclitaxel 199Fluorouracil 190Oxaliplatin 177Albumin-Bound Paclitaxel 154Capecitabine 137Leucovorin 133Irinotecan 114Radiotherapy 96Taxes 85pembrolizumab 81Cisplatin 73Erlotinib Hydrochloride 70Radiosurgery 69Nivolumab 56Drug Therapy 56Bevacizumab 54Magnetic Resonance Spectroscopy 51Cyclophosphamide 50folfirinox 45Specimen Handling 43Docetaxel 42Cetuximab 40Biopsy 39irinotecan sucrosofate 38S 1 (combination) 36Pancreaticoduodenectomy 35Blood Specimen Collection 34Surgical Procedures, Operative 31Paclitaxel 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × genexol-PM × Gastrointestinal × Clear all
NCT00882973 2017-05-05

Trial to Determine the Maximum Tolerated Dose of Genexol-PM Plus Gemcitabine and Evaluate Efficacy and Safety of Genexol-PM Regimens in Subjects With Advanced Pancreatic Cancer

Samyang Biopharmaceuticals Corporation

Phase 1 Completed
18 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT00111904 2011-12-14

Paclitaxel in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

National Cancer Institute (NCI)

Phase 2 Completed
43 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡